Two widely touted Alzheimer’s medications, lecanemab (Leqembi) and donanemab (Kisunla), have been shown to enable patients to remain in their homes, living independently, for longer periods of time. According to a recent study published in the Alzheimer’s Association journal, these medications can prolong independence by 10-29 months for patients with mild symptoms.
Researchers at Washington University School of Medicine analyzed data from 282 patients who took either lecanemab or donanemab and found that patients treated with these medications lived independently for 8-39 months longer than those without treatment. The study suggests that starting treatment early can maximize the potential benefits, but warns that the results may not translate to the general population due to the dedicated nature of the participants.
While the medications are effective in prolonging independence, they are not without risks and side effects. Dr. Chris Vercammen, a board-certified internal medicine physician, emphasized that lecanemab and donanemab do not stop or reverse Alzheimer’s disease, but can extend periods of independence for individuals in the early stages of the disease.
For those considering these treatments, it is essential to have an “in-depth conversation” with their doctor about the potential benefits and weigh them against the risks. The medications may be beneficial for people who are just starting treatment or have mild symptoms, but more research is needed to understand their impact on the general population.
Source: https://www.foxnews.com/health/two-alzheimers-drugs-help-patients-live-independently-home-longer-periods